The global market for Live Attenuated Influenza Vaccine (LAIV) is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Live Attenuated Influenza Vaccine (LAIV) market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Live Attenuated Influenza Vaccine (LAIV) market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Live Attenuated Influenza Vaccine (LAIV) market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Live Attenuated Influenza Vaccine (LAIV) market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Live Attenuated Influenza Vaccine (LAIV) players cover Sanofi Pasteur, AstraZeneca, CSL, Abbott and GlaxoSmithKline, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Live Attenuated Influenza Vaccine (LAIV) market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Live Attenuated Influenza Vaccine (LAIV) market, with both quantitative and qualitative data, to help readers understand how the Live Attenuated Influenza Vaccine (LAIV) market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.
Market Segmentation:
The study segments the Live Attenuated Influenza Vaccine (LAIV) market and forecasts the market size by Type (Trivalent Flu Vaccine and Quadrivalent Flu Vaccine,), by Application (Hospital, Clinic, Public Health Agency and Other), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Trivalent Flu Vaccine
Quadrivalent Flu Vaccine
Segmentation by application
Hospital
Clinic
Public Health Agency
Other
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
Sanofi Pasteur
AstraZeneca
CSL
Abbott
GlaxoSmithKline
Serum Institute
Fluenz Tetra
Cytiva
BioDiem
FluMist
GSK
ChangChun High & New Technology
BCHT Biotechnology
Chapter Introduction
Chapter 1: Scope of Live Attenuated Influenza Vaccine (LAIV), Research Methodology, etc.
Chapter 2: Executive Summary, global Live Attenuated Influenza Vaccine (LAIV) market size (sales and revenue) and CAGR, Live Attenuated Influenza Vaccine (LAIV) market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Live Attenuated Influenza Vaccine (LAIV) sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Live Attenuated Influenza Vaccine (LAIV) sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Live Attenuated Influenza Vaccine (LAIV) market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Sanofi Pasteur, AstraZeneca, CSL, Abbott, GlaxoSmithKline, Serum Institute, Fluenz Tetra, Cytiva and BioDiem, etc.
Chapter 14: Research Findings and Conclusion
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Live Attenuated Influenza Vaccine (LAIV) Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Live Attenuated Influenza Vaccine (LAIV) by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Live Attenuated Influenza Vaccine (LAIV) by Country/Region, 2017, 2022 & 2028
2.2 Live Attenuated Influenza Vaccine (LAIV) Segment by Type
2.2.1 Trivalent Flu Vaccine
2.2.2 Quadrivalent Flu Vaccine
2.3 Live Attenuated Influenza Vaccine (LAIV) Sales by Type
2.3.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2017-2022)
2.3.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue and Market Share by Type (2017-2022)
2.3.3 Global Live Attenuated Influenza Vaccine (LAIV) Sale Price by Type (2017-2022)
2.4 Live Attenuated Influenza Vaccine (LAIV) Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Public Health Agency
2.4.4 Other
2.5 Live Attenuated Influenza Vaccine (LAIV) Sales by Application
2.5.1 Global Live Attenuated Influenza Vaccine (LAIV) Sale Market Share by Application (2017-2022)
2.5.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue and Market Share by Application (2017-2022)
2.5.3 Global Live Attenuated Influenza Vaccine (LAIV) Sale Price by Application (2017-2022)
3 Global Live Attenuated Influenza Vaccine (LAIV) by Company
3.1 Global Live Attenuated Influenza Vaccine (LAIV) Breakdown Data by Company
3.1.1 Global Live Attenuated Influenza Vaccine (LAIV) Annual Sales by Company (2020-2022)
3.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Company (2020-2022)
3.2 Global Live Attenuated Influenza Vaccine (LAIV) Annual Revenue by Company (2020-2022)
3.2.1 Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Company (2020-2022)
3.2.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Company (2020-2022)
3.3 Global Live Attenuated Influenza Vaccine (LAIV) Sale Price by Company
3.4 Key Manufacturers Live Attenuated Influenza Vaccine (LAIV) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Live Attenuated Influenza Vaccine (LAIV) Product Location Distribution
3.4.2 Players Live Attenuated Influenza Vaccine (LAIV) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Live Attenuated Influenza Vaccine (LAIV) by Geographic Region
4.1 World Historic Live Attenuated Influenza Vaccine (LAIV) Market Size by Geographic Region (2017-2022)
4.1.1 Global Live Attenuated Influenza Vaccine (LAIV) Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Annual Revenue by Geographic Region
4.2 World Historic Live Attenuated Influenza Vaccine (LAIV) Market Size by Country/Region (2017-2022)
4.2.1 Global Live Attenuated Influenza Vaccine (LAIV) Annual Sales by Country/Region (2017-2022)
4.2.2 Global Live Attenuated Influenza Vaccine (LAIV) Annual Revenue by Country/Region
4.3 Americas Live Attenuated Influenza Vaccine (LAIV) Sales Growth
4.4 APAC Live Attenuated Influenza Vaccine (LAIV) Sales Growth
4.5 Europe Live Attenuated Influenza Vaccine (LAIV) Sales Growth
4.6 Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales Growth
5 Americas
5.1 Americas Live Attenuated Influenza Vaccine (LAIV) Sales by Country
5.1.1 Americas Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2017-2022)
5.1.2 Americas Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2017-2022)
5.2 Americas Live Attenuated Influenza Vaccine (LAIV) Sales by Type
5.3 Americas Live Attenuated Influenza Vaccine (LAIV) Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Live Attenuated Influenza Vaccine (LAIV) Sales by Region
6.1.1 APAC Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2017-2022)
6.1.2 APAC Live Attenuated Influenza Vaccine (LAIV) Revenue by Region (2017-2022)
6.2 APAC Live Attenuated Influenza Vaccine (LAIV) Sales by Type
6.3 APAC Live Attenuated Influenza Vaccine (LAIV) Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Live Attenuated Influenza Vaccine (LAIV) by Country
7.1.1 Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2017-2022)
7.1.2 Europe Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2017-2022)
7.2 Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Type
7.3 Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) by Country
8.1.1 Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2017-2022)
8.1.2 Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2017-2022)
8.2 Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Type
8.3 Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Live Attenuated Influenza Vaccine (LAIV)
10.3 Manufacturing Process Analysis of Live Attenuated Influenza Vaccine (LAIV)
10.4 Industry Chain Structure of Live Attenuated Influenza Vaccine (LAIV)
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Live Attenuated Influenza Vaccine (LAIV) Distributors
11.3 Live Attenuated Influenza Vaccine (LAIV) Customer
12 World Forecast Review for Live Attenuated Influenza Vaccine (LAIV) by Geographic Region
12.1 Global Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Region
12.1.1 Global Live Attenuated Influenza Vaccine (LAIV) Forecast by Region (2023-2028)
12.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Live Attenuated Influenza Vaccine (LAIV) Forecast by Type
12.7 Global Live Attenuated Influenza Vaccine (LAIV) Forecast by Application
13 Key Players Analysis
13.1 Sanofi Pasteur
13.1.1 Sanofi Pasteur Company Information
13.1.2 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Product Offered
13.1.3 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Sanofi Pasteur Main Business Overview
13.1.5 Sanofi Pasteur Latest Developments
13.2 AstraZeneca
13.2.1 AstraZeneca Company Information
13.2.2 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Product Offered
13.2.3 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 AstraZeneca Main Business Overview
13.2.5 AstraZeneca Latest Developments
13.3 CSL
13.3.1 CSL Company Information
13.3.2 CSL Live Attenuated Influenza Vaccine (LAIV) Product Offered
13.3.3 CSL Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 CSL Main Business Overview
13.3.5 CSL Latest Developments
13.4 Abbott
13.4.1 Abbott Company Information
13.4.2 Abbott Live Attenuated Influenza Vaccine (LAIV) Product Offered
13.4.3 Abbott Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Abbott Main Business Overview
13.4.5 Abbott Latest Developments
13.5 GlaxoSmithKline
13.5.1 GlaxoSmithKline Company Information
13.5.2 GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Product Offered
13.5.3 GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 GlaxoSmithKline Main Business Overview
13.5.5 GlaxoSmithKline Latest Developments
13.6 Serum Institute
13.6.1 Serum Institute Company Information
13.6.2 Serum Institute Live Attenuated Influenza Vaccine (LAIV) Product Offered
13.6.3 Serum Institute Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Serum Institute Main Business Overview
13.6.5 Serum Institute Latest Developments
13.7 Fluenz Tetra
13.7.1 Fluenz Tetra Company Information
13.7.2 Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Product Offered
13.7.3 Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Fluenz Tetra Main Business Overview
13.7.5 Fluenz Tetra Latest Developments
13.8 Cytiva
13.8.1 Cytiva Company Information
13.8.2 Cytiva Live Attenuated Influenza Vaccine (LAIV) Product Offered
13.8.3 Cytiva Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Cytiva Main Business Overview
13.8.5 Cytiva Latest Developments
13.9 BioDiem
13.9.1 BioDiem Company Information
13.9.2 BioDiem Live Attenuated Influenza Vaccine (LAIV) Product Offered
13.9.3 BioDiem Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 BioDiem Main Business Overview
13.9.5 BioDiem Latest Developments
13.10 FluMist
13.10.1 FluMist Company Information
13.10.2 FluMist Live Attenuated Influenza Vaccine (LAIV) Product Offered
13.10.3 FluMist Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 FluMist Main Business Overview
13.10.5 FluMist Latest Developments
13.11 GSK
13.11.1 GSK Company Information
13.11.2 GSK Live Attenuated Influenza Vaccine (LAIV) Product Offered
13.11.3 GSK Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 GSK Main Business Overview
13.11.5 GSK Latest Developments
13.12 ChangChun High & New Technology
13.12.1 ChangChun High & New Technology Company Information
13.12.2 ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Product Offered
13.12.3 ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 ChangChun High & New Technology Main Business Overview
13.12.5 ChangChun High & New Technology Latest Developments
13.13 BCHT Biotechnology
13.13.1 BCHT Biotechnology Company Information
13.13.2 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Product Offered
13.13.3 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2022)
13.13.4 BCHT Biotechnology Main Business Overview
13.13.5 BCHT Biotechnology Latest Developments
14 Research Findings and Conclusion
List of Tables
Table 1. Live Attenuated Influenza Vaccine (LAIV) Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Live Attenuated Influenza Vaccine (LAIV) Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Trivalent Flu Vaccine
Table 4. Major Players of Quadrivalent Flu Vaccine
Table 5. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2017-2022) & (K Units)
Table 6. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2017-2022)
Table 7. Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Type (2017-2022) & ($ million)
Table 8. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Type (2017-2022)
Table 9. Global Live Attenuated Influenza Vaccine (LAIV) Sale Price by Type (2017-2022) & (US$/Unit)
Table 10. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2017-2022) & (K Units)
Table 11. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2017-2022)
Table 12. Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Application (2017-2022)
Table 13. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Application (2017-2022)
Table 14. Global Live Attenuated Influenza Vaccine (LAIV) Sale Price by Application (2017-2022) & (US$/Unit)
Table 15. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Company (2020-2022) & (K Units)
Table 16. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Company (2020-2022)
Table 17. Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Company (2020-2022) ($ Millions)
Table 18. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Company (2020-2022)
Table 19. Global Live Attenuated Influenza Vaccine (LAIV) Sale Price by Company (2020-2022) & (US$/Unit)
Table 20. Key Manufacturers Live Attenuated Influenza Vaccine (LAIV) Producing Area Distribution and Sales Area
Table 21. Players Live Attenuated Influenza Vaccine (LAIV) Products Offered
Table 22. Live Attenuated Influenza Vaccine (LAIV) Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Geographic Region (2017-2022) & (K Units)
Table 26. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share Geographic Region (2017-2022)
Table 27. Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Geographic Region (2017-2022) & ($ millions)
Table 28. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Geographic Region (2017-2022)
Table 29. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Country/Region (2017-2022) & (K Units)
Table 30. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Country/Region (2017-2022)
Table 31. Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Country/Region (2017-2022) & ($ millions)
Table 32. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Country/Region (2017-2022)
Table 33. Americas Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2017-2022) & (K Units)
Table 34. Americas Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Country (2017-2022)
Table 35. Americas Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2017-2022) & ($ Millions)
Table 36. Americas Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Country (2017-2022)
Table 37. Americas Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2017-2022) & (K Units)
Table 38. Americas Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2017-2022)
Table 39. Americas Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2017-2022) & (K Units)
Table 40. Americas Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2017-2022)
Table 41. APAC Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2017-2022) & (K Units)
Table 42. APAC Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region (2017-2022)
Table 43. APAC Live Attenuated Influenza Vaccine (LAIV) Revenue by Region (2017-2022) & ($ Millions)
Table 44. APAC Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Region (2017-2022)
Table 45. APAC Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2017-2022) & (K Units)
Table 46. APAC Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2017-2022)
Table 47. APAC Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2017-2022) & (K Units)
Table 48. APAC Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2017-2022)
Table 49. Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2017-2022) & (K Units)
Table 50. Europe Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Country (2017-2022)
Table 51. Europe Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2017-2022) & ($ Millions)
Table 52. Europe Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Country (2017-2022)
Table 53. Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2017-2022) & (K Units)
Table 54. Europe Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2017-2022)
Table 55. Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2017-2022) & (K Units)
Table 56. Europe Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2017-2022)
Table 57. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2017-2022) & (K Units)
Table 58. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Country (2017-2022)
Table 59. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2017-2022) & ($ Millions)
Table 60. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Country (2017-2022)
Table 61. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2017-2022) & (K Units)
Table 62. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2017-2022)
Table 63. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2017-2022) & (K Units)
Table 64. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2017-2022)
Table 65. Key Market Drivers & Growth Opportunities of Live Attenuated Influenza Vaccine (LAIV)
Table 66. Key Market Challenges & Risks of Live Attenuated Influenza Vaccine (LAIV)
Table 67. Key Industry Trends of Live Attenuated Influenza Vaccine (LAIV)
Table 68. Live Attenuated Influenza Vaccine (LAIV) Raw Material
Table 69. Key Suppliers of Raw Materials
Table 70. Live Attenuated Influenza Vaccine (LAIV) Distributors List
Table 71. Live Attenuated Influenza Vaccine (LAIV) Customer List
Table 72. Global Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Region (2023-2028) & (K Units)
Table 73. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Forecast by Region
Table 74. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Forecast by Region (2023-2028) & ($ millions)
Table 75. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share Forecast by Region (2023-2028)
Table 76. Americas Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Country (2023-2028) & (K Units)
Table 77. Americas Live Attenuated Influenza Vaccine (LAIV) Revenue Forecast by Country (2023-2028) & ($ millions)
Table 78. APAC Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Region (2023-2028) & (K Units)
Table 79. APAC Live Attenuated Influenza Vaccine (LAIV) Revenue Forecast by Region (2023-2028) & ($ millions)
Table 80. Europe Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Country (2023-2028) & (K Units)
Table 81. Europe Live Attenuated Influenza Vaccine (LAIV) Revenue Forecast by Country (2023-2028) & ($ millions)
Table 82. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Country (2023-2028) & (K Units)
Table 83. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Revenue Forecast by Country (2023-2028) & ($ millions)
Table 84. Global Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Type (2023-2028) & (K Units)
Table 85. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share Forecast by Type (2023-2028)
Table 86. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 87. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share Forecast by Type (2023-2028)
Table 88. Global Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Application (2023-2028) & (K Units)
Table 89. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share Forecast by Application (2023-2028)
Table 90. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 91. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share Forecast by Application (2023-2028)
Table 92. Sanofi Pasteur Basic Information, Live Attenuated Influenza Vaccine (LAIV) Manufacturing Base, Sales Area and Its Competitors
Table 93. Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Product Offered
Table 94. Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 95. Sanofi Pasteur Main Business
Table 96. Sanofi Pasteur Latest Developments
Table 97. AstraZeneca Basic Information, Live Attenuated Influenza Vaccine (LAIV) Manufacturing Base, Sales Area and Its Competitors
Table 98. AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Product Offered
Table 99. AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 100. AstraZeneca Main Business
Table 101. AstraZeneca Latest Developments
Table 102. CSL Basic Information, Live Attenuated Influenza Vaccine (LAIV) Manufacturing Base, Sales Area and Its Competitors
Table 103. CSL Live Attenuated Influenza Vaccine (LAIV) Product Offered
Table 104. CSL Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 105. CSL Main Business
Table 106. CSL Latest Developments
Table 107. Abbott Basic Information, Live Attenuated Influenza Vaccine (LAIV) Manufacturing Base, Sales Area and Its Competitors
Table 108. Abbott Live Attenuated Influenza Vaccine (LAIV) Product Offered
Table 109. Abbott Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 110. Abbott Main Business
Table 111. Abbott Latest Developments
Table 112. GlaxoSmithKline Basic Information, Live Attenuated Influenza Vaccine (LAIV) Manufacturing Base, Sales Area and Its Competitors
Table 113. GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Product Offered
Table 114. GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 115. GlaxoSmithKline Main Business
Table 116. GlaxoSmithKline Latest Developments
Table 117. Serum Institute Basic Information, Live Attenuated Influenza Vaccine (LAIV) Manufacturing Base, Sales Area and Its Competitors
Table 118. Serum Institute Live Attenuated Influenza Vaccine (LAIV) Product Offered
Table 119. Serum Institute Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 120. Serum Institute Main Business
Table 121. Serum Institute Latest Developments
Table 122. Fluenz Tetra Basic Information, Live Attenuated Influenza Vaccine (LAIV) Manufacturing Base, Sales Area and Its Competitors
Table 123. Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Product Offered
Table 124. Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 125. Fluenz Tetra Main Business
Table 126. Fluenz Tetra Latest Developments
Table 127. Cytiva Basic Information, Live Attenuated Influenza Vaccine (LAIV) Manufacturing Base, Sales Area and Its Competitors
Table 128. Cytiva Live Attenuated Influenza Vaccine (LAIV) Product Offered
Table 129. Cytiva Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 130. Cytiva Main Business
Table 131. Cytiva Latest Developments
Table 132. BioDiem Basic Information, Live Attenuated Influenza Vaccine (LAIV) Manufacturing Base, Sales Area and Its Competitors
Table 133. BioDiem Live Attenuated Influenza Vaccine (LAIV) Product Offered
Table 134. BioDiem Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 135. BioDiem Main Business
Table 136. BioDiem Latest Developments
Table 137. FluMist Basic Information, Live Attenuated Influenza Vaccine (LAIV) Manufacturing Base, Sales Area and Its Competitors
Table 138. FluMist Live Attenuated Influenza Vaccine (LAIV) Product Offered
Table 139. FluMist Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 140. FluMist Main Business
Table 141. FluMist Latest Developments
Table 142. GSK Basic Information, Live Attenuated Influenza Vaccine (LAIV) Manufacturing Base, Sales Area and Its Competitors
Table 143. GSK Live Attenuated Influenza Vaccine (LAIV) Product Offered
Table 144. GSK Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 145. GSK Main Business
Table 146. GSK Latest Developments
Table 147. ChangChun High & New Technology Basic Information, Live Attenuated Influenza Vaccine (LAIV) Manufacturing Base, Sales Area and Its Competitors
Table 148. ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Product Offered
Table 149. ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 150. ChangChun High & New Technology Main Business
Table 151. ChangChun High & New Technology Latest Developments
Table 152. BCHT Biotechnology Basic Information, Live Attenuated Influenza Vaccine (LAIV) Manufacturing Base, Sales Area and Its Competitors
Table 153. BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Product Offered
Table 154. BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 155. BCHT Biotechnology Main Business
Table 156. BCHT Biotechnology Latest Developments
List of Figures
Figure 1. Picture of Live Attenuated Influenza Vaccine (LAIV)
Figure 2. Live Attenuated Influenza Vaccine (LAIV) Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Live Attenuated Influenza Vaccine (LAIV) Sales Growth Rate 2017-2028 (K Units)
Figure 7. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Trivalent Flu Vaccine
Figure 10. Product Picture of Quadrivalent Flu Vaccine
Figure 11. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type in 2021
Figure 12. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Type (2017-2022)
Figure 13. Live Attenuated Influenza Vaccine (LAIV) Consumed in Hospital
Figure 14. Global Live Attenuated Influenza Vaccine (LAIV) Market: Hospital (2017-2022) & (K Units)
Figure 15. Live Attenuated Influenza Vaccine (LAIV) Consumed in Clinic
Figure 16. Global Live Attenuated Influenza Vaccine (LAIV) Market: Clinic (2017-2022) & (K Units)
Figure 17. Live Attenuated Influenza Vaccine (LAIV) Consumed in Public Health Agency
Figure 18. Global Live Attenuated Influenza Vaccine (LAIV) Market: Public Health Agency (2017-2022) & (K Units)
Figure 19. Live Attenuated Influenza Vaccine (LAIV) Consumed in Other
Figure 20. Global Live Attenuated Influenza Vaccine (LAIV) Market: Other (2017-2022) & (K Units)
Figure 21. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2017-2022)
Figure 22. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Application in 2021
Figure 23. Live Attenuated Influenza Vaccine (LAIV) Revenue Market by Company in 2021 ($ Million)
Figure 24. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Company in 2021
Figure 25. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Geographic Region (2017-2022)
Figure 26. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Geographic Region in 2021
Figure 27. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region (2017-2022)
Figure 28. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Country/Region in 2021
Figure 29. Americas Live Attenuated Influenza Vaccine (LAIV) Sales 2017-2022 (K Units)
Figure 30. Americas Live Attenuated Influenza Vaccine (LAIV) Revenue 2017-2022 ($ Millions)
Figure 31. APAC Live Attenuated Influenza Vaccine (LAIV) Sales 2017-2022 (K Units)
Figure 32. APAC Live Attenuated Influenza Vaccine (LAIV) Revenue 2017-2022 ($ Millions)
Figure 33. Europe Live Attenuated Influenza Vaccine (LAIV) Sales 2017-2022 (K Units)
Figure 34. Europe Live Attenuated Influenza Vaccine (LAIV) Revenue 2017-2022 ($ Millions)
Figure 35. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales 2017-2022 (K Units)
Figure 36. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Revenue 2017-2022 ($ Millions)
Figure 37. Americas Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Country in 2021
Figure 38. Americas Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Country in 2021
Figure 39. United States Live Attenuated Influenza Vaccine (LAIV) Revenue Growth 2017-2022 ($ Millions)
Figure 40. Canada Live Attenuated Influenza Vaccine (LAIV) Revenue Growth 2017-2022 ($ Millions)
Figure 41. Mexico Live Attenuated Influenza Vaccine (LAIV) Revenue Growth 2017-2022 ($ Millions)
Figure 42. Brazil Live Attenuated Influenza Vaccine (LAIV) Revenue Growth 2017-2022 ($ Millions)
Figure 43. APAC Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region in 2021
Figure 44. APAC Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Regions in 2021
Figure 45. China Live Attenuated Influenza Vaccine (LAIV) Revenue Growth 2017-2022 ($ Millions)
Figure 46. Japan Live Attenuated Influenza Vaccine (LAIV) Revenue Growth 2017-2022 ($ Millions)
Figure 47. South Korea Live Attenuated Influenza Vaccine (LAIV) Revenue Growth 2017-2022 ($ Millions)
Figure 48. Southeast Asia Live Attenuated Influenza Vaccine (LAIV) Revenue Growth 2017-2022 ($ Millions)
Figure 49. India Live Attenuated Influenza Vaccine (LAIV) Revenue Growth 2017-2022 ($ Millions)
Figure 50. Australia Live Attenuated Influenza Vaccine (LAIV) Revenue Growth 2017-2022 ($ Millions)
Figure 51. Europe Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Country in 2021
Figure 52. Europe Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Country in 2021
Figure 53. Germany Live Attenuated Influenza Vaccine (LAIV) Revenue Growth 2017-2022 ($ Millions)
Figure 54. France Live Attenuated Influenza Vaccine (LAIV) Revenue Growth 2017-2022 ($ Millions)
Figure 55. UK Live Attenuated Influenza Vaccine (LAIV) Revenue Growth 2017-2022 ($ Millions)
Figure 56. Italy Live Attenuated Influenza Vaccine (LAIV) Revenue Growth 2017-2022 ($ Millions)
Figure 57. Russia Live Attenuated Influenza Vaccine (LAIV) Revenue Growth 2017-2022 ($ Millions)
Figure 58. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Country in 2021
Figure 59. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Country in 2021
Figure 60. Egypt Live Attenuated Influenza Vaccine (LAIV) Revenue Growth 2017-2022 ($ Millions)
Figure 61. South Africa Live Attenuated Influenza Vaccine (LAIV) Revenue Growth 2017-2022 ($ Millions)
Figure 62. Israel Live Attenuated Influenza Vaccine (LAIV) Revenue Growth 2017-2022 ($ Millions)
Figure 63. Turkey Live Attenuated Influenza Vaccine (LAIV) Revenue Growth 2017-2022 ($ Millions)
Figure 64. GCC Country Live
Global Freckle-removing Medical and Beau..
The global market for Freckle-removing Medical and Beauty Eq..
+16467917070US (Toll Free)